Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers
- 1 March 2009
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 112 (3) , 475-480
- https://doi.org/10.1016/j.ygyno.2008.11.031
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinomaHuman Pathology, 2007
- Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CAMolecular and Cellular Biology, 2007
- Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)European Journal Of Cancer, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Distinct subtypes of serous ovarian carcinoma identified by p53 determination☆Gynecologic Oncology, 2003
- Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patientsEuropean Journal of Clinical Investigation, 2003
- PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapyInternational Journal of Cancer, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissuesEuropean Journal Of Cancer, 2001
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998